Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Upgrades are coming to Alix Goolden Performance Hall as part of a city grant, and could include a plaza co-created with Our ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

It endures for weeks or months. Sadness turns people inward, encouraging them to find meaning or other accommodation, and then remits. Depression requires treatment; sadness does not. How does ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Situations may not be subject to change—but attitudes, interpretation, and meaning of experience are always under individual control and can confer resistance to depression and other disorders..

Paula Badosa was overcome with emotions when she hit a forehand winner to seal a 7-5, 6-4 win over Coco Gauff in the ...